Takeda Pharmaceutical/$TAK
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Takeda Pharmaceutical
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
Ticker
$TAK
Sector
Primary listing
NYSE
Employees
47,455
Headquarters
Tokyo, Japan
Website
TAK Metrics
BasicAdvanced
$55B
39.52
$0.45
0.08
$0.53
2.84%
Price and volume
Market cap
$55B
Beta
0.08
52-week high
$17.83
52-week low
$12.99
Average daily volume
3.1M
Dividend rate
$0.53
Financial strength
Current ratio
1.194
Quick ratio
0.541
Long term debt to equity
55.862
Total debt to equity
70.93
Dividend payout ratio (TTM)
277.04%
Interest coverage (TTM)
4.62%
Profitability
EBITDA (TTM)
8,115.106
Gross margin (TTM)
65.52%
Net profit margin (TTM)
2.53%
Operating margin (TTM)
13.51%
Effective tax rate (TTM)
44.89%
Revenue per employee (TTM)
$599,280
Management effectiveness
Return on assets (TTM)
2.47%
Return on equity (TTM)
1.50%
Valuation
Price to earnings (TTM)
39.52
Price to revenue (TTM)
0.983
Price to book
1.13
Price to tangible book (TTM)
-5.33
Price to free cash flow (TTM)
5.859
Free cash flow yield (TTM)
17.07%
Free cash flow per share (TTM)
3.028
Dividend yield (TTM)
2.97%
Forward dividend yield
2.84%
Growth
Revenue change (TTM)
-2.50%
Earnings per share change (TTM)
-45.86%
3-year revenue growth (CAGR)
4.21%
10-year revenue growth (CAGR)
9.32%
3-year earnings per share growth (CAGR)
-26.17%
10-year earnings per share growth (CAGR)
-6.81%
3-year dividend per share growth (CAGR)
3.23%
10-year dividend per share growth (CAGR)
0.96%
What the Analysts think about TAK
Analyst ratings (Buy, Hold, Sell) for Takeda Pharmaceutical stock.
TAK Financial Performance
Revenues and expenses
TAK News
AllArticlesVideos
Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead
Business Wire·7 days ago
Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1
Business Wire·2 weeks ago
Takeda's AI-crafted psoriasis pill succeeds in late-stage studies
Reuters·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Takeda Pharmaceutical stock?
Takeda Pharmaceutical (TAK) has a market cap of $55B as of February 05, 2026.
What is the P/E ratio for Takeda Pharmaceutical stock?
The price to earnings (P/E) ratio for Takeda Pharmaceutical (TAK) stock is 39.52 as of February 05, 2026.
Does Takeda Pharmaceutical stock pay dividends?
Yes, the Takeda Pharmaceutical (TAK) stock pays dividends to shareholders. As of February 05, 2026, the dividend rate is $0.52765 and the yield is 2.84%. Takeda Pharmaceutical has a payout ratio of 277.04% on a trailing twelve-month basis.
When is the next Takeda Pharmaceutical dividend payment date?
The next Takeda Pharmaceutical (TAK) dividend payment date is unconfirmed.
What is the beta indicator for Takeda Pharmaceutical?
Takeda Pharmaceutical (TAK) has a beta rating of 0.08. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.